Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic Nephropathy

Sponsor
The First Affiliated Hospital of Dalian Medical University
Study ID
NCT05418465
Status
Unknown

Conditions

  • Diabetic Nephropathies

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Huangqi Guizhi Wuwu decoction — DRUG
    Huangqi Guizhi Wuwu decoction, 100ml at a time, 2 times a day. Oral administration.
  • Dapagliflozin — DRUG
    Dapagliflozin, 10mg at a time, once a day. Oral administration.

Study Details

This is a prospective, open, multicenter clinical trial.The objective of this study is to evaluate the efficacy and safety of Huangqi Guizhi Wuwu Decoction in patients with CKD stage 2-4 diabetic nephropathy.

Key Dates

Start date
Jan 26, 2022
Status verified
Jun 2022
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022

Study Design

Enrollment
100 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Huangqi Guizhi Wuwu decoction group
    Huangqi Guizhi Wuwu decoction
  • Active Comparator: Dapagliflozin group
    Dapagliflozin

Primary Outcome Measure

Rate of change in Estimated Glomerular Filtration Rate (eGFR) compared to baseline [ Time Frame: 12 weeks ]

Related Studies